[The efficacy of a new medication -- intranasal glucocorticoid mometasone furoate (Nasonex) -- in seasonal allergic rhinitis].

The aim of this open study was to evaluate the efficacy and safety of new topical corticosteroid Nasonex (mometasone furoate) in allergic, seasonal rhinitis. The investigations were carried out on 30 patients with proven grass pollen allergy. Nasonex was administered intranasally during the pollen season, in a single dose 200 micrograms.

[Loratadine in the treatment of seasonal allergic rhinitis].

A single blind, placebo-controlled, parallel-group study was performed during a pollen season in 41 patients suffering from seasonal allergic rhinitis. A group of 26 patients was treated with loratadine (10 mg daily in one dose) for 3 weeks. Placebo was given in the group of 15 patients (1 tablet daily) during 8-10 days.

[The effect of loratadine on skin and bronchial reactivity and histamine liberation from basophils in patients with atopic asthma and allergic rhinitis].

The effect of the therapy with Loratadine on skin and bronchial reactivity to histamine and on a specific histamine release from isolated basophils of allergic patients was assessed. The studies were carried out on a 34 patients (23 with pollen rhinitis and 11 with a mild bronchial asthma). The effect loratadine versus placebo on the skin reactivity to histamine was measured in patients suffering from pollen rhinitis.